As we near the end of this remarkable year, we're thrilled to reflect on the incredible milestones and successes that the UC Davis Institute for Psychedelics and Neurotherapeutics (IPN) has achieved. As the first institute of its kind funded by a major public university, we are working hard to make sure that initial investment leads to tangible benefits for the public. Already, our groundbreaking research and innovative work have been featured in over 220 media articles (click here for selected articles). A true highlight of the year was our feature in a PBS KVIE special[DO1] . This captivating program delves into the potential of psychedelic therapy, shedding light on how it might transform the landscape of mental health treatment.
These accomplishments, among many others, underscore the dedication, passion, and commitment of our team and partners to establish a new paradigm in mental health. We look forward to a year of continued growth and discovery in the field of psychedelics and neurotherapeutics. Thank you for your unwavering support of our mission!
The IPN is going to have a physical home! Early next year, we will unveil our state-of-the-art facility in the new wing of the Chemistry building, strategically located in the center of the UC Davis main campus in close proximity to the Department of Psychology, the College of Biological Sciences, and only a short bike ride away from the Center for Neuroscience and the Health Sciences District. This cutting-edge space will house our proprietary CNS-specific compound library and be used for pharmacological screening. It is set to be a hub of innovation, fostering interdisciplinary research and collaboration related to neurotherapeutics. Stay tuned for more updates regarding our ribbon cutting ceremony! Below is an exclusive look at the building plans!
We are thrilled to announce that our very own Associate Director, Dr. John A. Gray, has taken on a new role as the Director of the M.D./Ph.D. Dual Degree Program at the UC Davis School of Medicine where he will help guide the next generation of physician-scientists advancing medical science from the bench to the bedside. This remarkable achievement highlights his dedication to advancing education, mentorship, and the pursuit of scientific and clinical excellence. We congratulate Dr. Gray on this prestigious appointment and are confident that his passion for science will continue to inspire future leaders in the field of medicine and beyond.
Technology invented at the Institute for Psychedelics and Neurotherapeutics at the University of California, Davis has been further developed by Delix Therapeutics, leading to a groundbreaking clinical trial of DLX-001, the first non-hallucinogenic psychoplastogen to be approved for human trials. Delix's phase I clinical trial has successfully completed dosing for the initial group of participants. The trial demonstrated the compound's predicted behavior in humans, without major safety concerns or hallucinogenic effects. Now that the comprehensive Phase I data is accessible, the collaboration between Delix Therapeutics and the Institute for Psychedelics and Neurotherapeutics brings hope for the development of transformative therapies for mental health disorders.